SCM
OLMA icon

Silverarc Capital Management’s Olema Pharmaceuticals OLMA Stock Holding History

Silverarc Capital Management’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-206,280
Closed -$5.16M – 83
2025
Q4 		$5.16M Sell
206,280
-727,261
-78% -$12.9M 0.72% 39
2025
Q3 		$9.14M Buy
+933,541
New +$5.61M 1.23% 28
2025
Q1 		– Sell
-233,281
Closed -$1.36M – 76
2024
Q4 		$1.36M Sell
233,281
-221,801
-49% -$2.22M 0.3% 52
2024
Q3 		$5.43M Sell
455,082
-91,781
-17% -$1.17M 1.22% 28
2024
Q2 		$5.92M Buy
546,863
+31,546
+6% +$342K 1.4% 25
2024
Q1 		$5.83M Sell
515,317
-58,513
-10% -$755K 1.62% 24
2023
Q4 		$8.05M Buy
573,830
+166,029
+41% +$2.23M 2.4% 13
2023
Q3 		$5.04M Buy
407,801
+17,335
+4% +$177K 1.53% 29
2023
Q2 		$3.53M Buy
+390,466
New +$2.36M 1.09% 31

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Silverarc Capital Management's OLMA Position: Q1 2026 in Review

Silverarc Capital Management sold out of Olema Pharmaceuticals (OLMA) in Q1 2026, closing a stake of 206,280 shares — an estimated $5.16M sold.

Silverarc Capital Management first reported a position in OLMA in Q2 2023 and held it in 9 quarters. The position peaked at $9.14M in Q3 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Silverarc Capital Management reported no remaining Olema Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 206,280 Olema Pharmaceuticals shares in Q1 2026, an estimated $5.16M.
  • Silverarc Capital Management first reported a position in Olema Pharmaceuticals in Q2 2023 and held it in 9 quarters.
  • Silverarc Capital Management's Olema Pharmaceuticals position peaked at $9.14M in Q3 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.